These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 7585591)

  • 1. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
    Asano M; Yukita A; Matsumoto T; Kondo S; Suzuki H
    Cancer Res; 1995 Nov; 55(22):5296-301. PubMed ID: 7585591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo.
    Asano M; Yukita A; Matsumoto T; Hanatani M; Suzuki H
    Hybridoma; 1998 Apr; 17(2):185-90. PubMed ID: 9627059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.
    Kondo S; Asano M; Suzuki H
    Biochem Biophys Res Commun; 1993 Aug; 194(3):1234-41. PubMed ID: 7688963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and characterization of neutralizing monoclonal antibodies to human vascular endothelial growth factor/vascular permeability factor121 (VEGF/VPF121).
    Asano M; Yukita A; Matsumoto T; Matsuo K; Kondo S; Suzuki H
    Hybridoma; 1995 Oct; 14(5):475-80. PubMed ID: 8575796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
    Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
    Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model.
    Melnyk O; Zimmerman M; Kim KJ; Shuman M
    J Urol; 1999 Mar; 161(3):960-3. PubMed ID: 10022734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
    Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis.
    Claffey KP; Brown LF; del Aguila LF; Tognazzi K; Yeo KT; Manseau EJ; Dvorak HF
    Cancer Res; 1996 Jan; 56(1):172-81. PubMed ID: 8548760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
    Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors.
    Zielke A; Middeke M; Hoffmann S; Colombo-Benkmann M; Barth P; Hassan I; Wunderlich A; Hofbauer LC; Duh QY
    Surgery; 2002 Dec; 132(6):1056-63; discussion 1063. PubMed ID: 12490855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.
    Luo JC; Toyoda M; Shibuya M
    Cancer Res; 1998 Jun; 58(12):2594-600. PubMed ID: 9635584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor.
    Hori A; Sasada R; Matsutani E; Naito K; Sakura Y; Fujita T; Kozai Y
    Cancer Res; 1991 Nov; 51(22):6180-4. PubMed ID: 1718597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of antibody against vascular endothelial growth factor on tumor growth].
    Wang G; Wang N; Liu T
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):163-6. PubMed ID: 10920886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
    Takayama K; Ueno H; Nakanishi Y; Sakamoto T; Inoue K; Shimizu K; Oohashi H; Hara N
    Cancer Res; 2000 Apr; 60(8):2169-77. PubMed ID: 10786681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.